- The U.S. government has secured 66 million doses of Moderna Inc's MRNA COVID-19 vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate containing Spikevax plus the omicron BA.4/5 strain mRNA.
- The contract includes an award of up to $1.74 billion for manufacturing and delivering 66 million doses of mRNA-1273.222 and options to purchase up to an additional 234 million doses of COVID-19 vaccine booster candidates.
- In June, Moderna released new data showing that one month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the omicron subvariants.
- Also Read: Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine.
- Earlier this month, Moderna announced that it is advancing two bivalent candidates for the fall based on different population health security strategies in different countries.
- mRNA-1273.222 contains the BA.4/5 Omicron strain, while mRNA-1273.214 contains the BA.1 omicron strain.
- Price Action: MRNA shares are up 3.06% at $162.91 during the premarket session on the last check Friday.
- Photo via Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechGovernmentLarge CapNewsHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccinewhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
